A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment.
The authors compared the ocular hypotensive efficacy of two different treatment regimens of levobunolol 0.5% in a double-masked, randomized, controlled clinical trial. Seventy-one patients with open-angle glaucoma or ocular hypertension received levobunolol 0.5% as their sole glaucoma medication either on a once-daily or twice-daily treatment regimen for 3 months. Approximately 81% of the patients in the once-daily treatment group and 88% of subjects in the twice-daily treatment group successfully completed the 3-month study period. The overall mean decrease in intraocular pressure (IOP) was 4.5 mmHg in the once-daily group and 5.6 mmHg in the twice-daily group. These differences were not statistically different. For both treatment groups, effects on mean heart rate and blood pressure were minimal. The authors' data from this population suggest that once-daily treatment with levobunolol is an effective glaucoma regimen.
Rakofsky
S I
SI
University of Miami, Florida.
Melamed
S
S
Cohen
J S
JS
Slight
J R
JR
Spaeth
G
G
Lewis
R A
RA
Zbrowski-Gutman
L
L
Eto
C Y
CY
Lue
J C
JC
Novack
G D
GD
D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D002040:Levobunolol / Q000008:administration & dosage* / Q000627:therapeutic use; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation
D002040:Levobunolol